Jul. 13 at 2:03 AM
$IMMP Overall positive takeaway: Despite the disappointment of TACTI-004, this announcement shifts attention back to the very strong survival data from INSIGHT-003. The company now has both compelling efficacy results and a clear scientific investigation into why the Phase III trial differed. If the root cause is identified and is addressable, the encouraging INSIGHT-003 survival data could become a significant asset for Immutep's future development program.
